| ISSN |
1948-9366 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Comparison of efficacy and safety of nab-paclitaxel and oxaliplatin + S-1 and standard S-1 and oxaliplatin chemotherapy regimens for treatment of gastric cancer
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Yi-Cong Wang, Long Feng, Gong-Ping Wang, Peng-Jie Yu, Can Guo, Bao-Jia Cai, Yan Song, Ting Pan, Bo-Hao Lin, Yuan-Dong Li and Jing-jing Xiao |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| The Department of Science and Technology of Qinghai Province |
2018-SF-113 |
| "Kunlun Talents-Plateau Famous Doctors" Project in Qinghai Province |
|
|
| Corresponding Author |
Peng-Jie Yu, Doctor, DPhil, PhD, Deputy Director, Research Fellow, Surgeon, Department of Gastrointestinal Surgery, The Affiliated Hospital of Qinghai University, No. 29 Tongren Road, Xining 810000, Qinghai Province, China. hnypj768@126.com |
| Key Words |
Nab-paclitaxel; Gastric cancer; Efficacy; Safety |
| Core Tip |
NaB-paclitaxel combined with oxaliplatin + S-1 (P-SOX) regimen is superior to conventional SOX regimen in the treatment of gastric cancer. Progression-free survival was associated with effective perioperative chemotherapy (Response Evaluation Criteria in Solid Tumors 1.1, Tumor Regression Grade), tumor diameter ≤ 2 cm, high differentiation, and early cTNM staging. |
| Publish Date |
2024-09-28 04:34 |
| Citation |
<p>Wang YC, Feng L, Wang GP, Yu PJ, Guo C, Cai BJ, Song Y, Pan T, Lin BH, Li YD, Xiao JJ. Comparison of efficacy and safety of nab-paclitaxel and oxaliplatin + S-1 and standard S-1 and oxaliplatin chemotherapy regimens for treatment of gastric cancer. <i>World J Gastrointest Surg</i> 2024; 16(10): 3224-3238</p> |
| URL |
https://www.wjgnet.com/1948-9366/full/v16/i10/3224.htm |
| DOI |
https://dx.doi.org/10.4240/wjgs.v16.i10.3224 |
